The SARS-CoV-2 pandemic has now been active for almost three years. Many issues were initially pointed out about the impact of this pandemic on pregnant women, the course of their pregnancy and possible complications regarding neonatal outcome. Similarly, the impact of pregnancy status on the natural history of SARS-CoV-2 infection was the subject of many questions. Many efforts were made to answer all these questions rapidly in order to optimize the management of pregnant women likely to be infected with SARS-CoV-2. The first data were quickly published and showed that SARS-CoV-2 was responsible for increased morbidity and mortality in pregnant women [1,2]. However, the speed of publication was counterbalanced by recurrent biases related to the retrospective nature of the studies and the absence of control groups in a large number of studies reported during the first year of the pandemic [3].

In order to improve the quality of understanding of the impact of COVID-19 on pregnant women, several prospective multicenter studies were set up, including the COVIPREG study. The COVIPREG study was historically designed to study COVID-19 seroprevalence in pregnant women at the time of delivery, the consequences of the infection for the women and their newborns and the risk factors of the disease. The first data from the COVIPREG study concerned the seroprevalence investigation between April 29 and June 26, 2020. It was shown that the seroprevalence (IgG-positive) was low (less than 5%) among the women included in one of the Parisian maternity hospitals of the COVIPREG study [4].

This new study investigated the impact of SARS-CoV-2 infection contracted during the 2nd and 3rd trimesters of pregnancy on the course of pregnancy in pregnant women included in the COVIPREG study.